Homepage Top Section2

The randomised and global phase III study will evaluate the efficacy of Farxiga as a treatment in patients hospitalised with COVID-19 who are at risk of developing serious

Systemic sclerosis (SSc), also called as scleroderma, is a disfiguring, disabling and fatal rare autoimmune disease. Nintedanib is a tyrosine kinase inhibitor designed to target crucial receptors engaged

The trial dubbed CheckMate -743 saw the Opdivo, Yervoy combination delivered a statistically significant and clinically meaningful improvement in overall survival (OS) compared to chemotherapy comprised of pemetrexed

The Danish pharma company said that the four-week fixed dose, blinded portion of PaTH Forward, which is assessing the safety, tolerability and efficacy of TransCon PTH in the

According to the agreement, Moderna will use BARDA’s funding to advance its mRNA-1273 vaccine candidate to FDA licensure. The mRNA-1273 is a vaccine candidate against SARS-CoV-2 encoding for

The Chinese biopharmaceutical company said that it has been developing the COVID-19 vaccine candidate since January 2020. The firm claimed that its scientists have quickly completed comprehensive preclinical

In this regard, Hope Biosciences will be evaluating the safety and efficacy of its adipose-derived mesenchymal stem cells (HB-adMSCs) in the mid-stage clinical trial. The phase 2 trial,

The pharma company has signed an agreement with the US National Institute of Allergy and Infectious Diseases (NIAID) to investigate baricitinib as an arm in the latter’s Adaptive

The FDA approval was based on positive data from the National Cancer Institute (NCI) Cancer Therapy Evaluation Programme (CTEP)-sponsored phase II SPRINT Stratum 1 study organised by the